Delta, Kelowna, BC – June 8, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site,
www.potcasts.ca
release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas Potcasts #573, Cannabis News and Stocks on the Move; (CSE: DELC) (OTCQB: DELCF), (TSXV: MUSH), (CSE: CURA) (OTCQX: CURLF), (TSXV: KHRN) (OTCQX: KHRNF)
SHARE PODCAST:
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com “Potcast” featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few private and public company announcements.
Delic Holdings Inc. (
CSE: DELC
) (
OTCQB: DELCF
), a leading psychedelic wellness platform
has signed a definitive agreement
to acquire Ketamine Infusion Centers LLC. KIC is a limited liability corporation formed under the laws of Arizona, which owns and operates two ketamine infusion treatment clinics, one in Phoenix, Arizona and the other in Bakersfield, California.
Supported by clinical trials and peer reviewed studies, ketamine infusions have emerged as a promising treatment option for chronic diseases and pain disorders. The successful completion of the transaction will bring a physical retail footprint to the DELIC ecosystem where it can leverage its IP, product development and audience capture through its various leading media properties.
Transaction Highlights
- The Transaction establishes DELIC as a diversified psychedelics organization. KIC has been growing steadily with revenues in excess of USD$1.5 million since 2019
- KIC will be one of the largest ketamine clinics, pending recently announced expansion. KIC will double its footprint to four (4) physical locations in California and Arizona
- KIC will be strategically positioned to leverage DELIC platform and brand: DELIC expects to drive patients to KIC through its media platform and become a national leader
- Established history of providing ketamine infusion services. The management team at KIC has been in business for 3 years expanding services throughout the United States
- Management expertise. The acquisition of KIC will add a team of 6 medical professionals and employees bringing a wealth of industry experience and knowledge to DELIC
Matt Stang, Founder and CEO of DELIC commented, “We publicly listed DELIC with the intent of buying cash-flowing, scalable companies and that is exactly what KIC represents. We are focused on making psychedelic wellness truly accessible, and this is a huge development in the realization of that vision.”
Sonny Diaz, Co-Founder of KIC stated, “We were thrilled to be joining the DELIC platform as we feel their patient acquisition strategy – using DELIC’s media platform to drive patients – is a game changer for scaling our clinics and expanding patient access. With a history of profitability and a management team with decades of experience in the health sector and successful exits of over two dozen clinics and hospitals, KIC’s extensive background in operating clinics and hospitals will enable DELIC to be the leader in legal psychedelic treatment clinics.
By acquiring KIC, DELIC expands from its hub of psychedelic education, media, and information properties and licensed lab and IP company (CBDV) to the ability to provide patients with psychedelic therapy. DELIC is uniquely positioned to bring digital awareness to its various holdings under the DELIC umbrella, and drive online users to brick and mortar clinics.
Over the last 3 years, the team at KIC has expanded from Arizona to California, while overseeing 4,000 treatments delivered to date, and generating over USD$1.5MM in revenue. KIC will operate under the DELIC umbrella, under the direction and guidance of Dr. Christopher Ray, Sonny Diaz, Rogelio Monzon, and Ganesh Acharya.
The Good Shroom Co Inc. (
TSXV: MUSH
), a Quebec based company that manufactures functional beverages under its two brands: Teonan and Velada,
has signed an agreement
with Mr. Rob Leichman, President of The Lyric Group, LLC, a leading business development consultant with a particular expertise in consumer-packaged goods distribution. TGSC has also initiated a podcast marketing campaign with AdvertiseCast to continue expanding their e-commerce presence throughout North America.
Lyric Group, LLC to Lead US Distribution.
The Lyric Group, LLC launches emerging and established food and beverage brands onto retail shelves throughout the US. Mr. Leichman and TGSC have come to an agreement whereby he will lead TGSC’s US distribution starting in key states by utilizing his varied list of established buyer, distributor and merchandizing relationships across multiple channels to launch the Teonan products. The Tri-State area (New York. New Jersey and Connecticut) will be the primary focus and used along with the pacific northwest and northern California.
The Lyric Group will manage strategy execution from logistics to product placement on retail shelves alongside the TGSC operations team. TGSC expects to launch its products in the fall of 2021.
E-commerce Expansion: Podcast
Over 100 million Americans have listened to a podcast in the last month and the projected amount of podcast ad spend by the end of the year is over $1 billion. Additionally, a survey of 300,000 listeners found that 63% of people bought something a host had promoted on their show.
In order to continue expanding its e-commerce presence TGSC has initiated Advertise Cast, one of the premier US podcast advertising networks to manage its podcast marketing. Advertise Cast and TGSC have identified strategic podcasters based on the quantity of listeners versus their demographics and will be marketing its products through podcaster reviews and targeted ads in various forms. Through this agreement, the Company will gain exposure to a targeted portion of Advertise Casts’s monthly listener reach of over 40,000,000. *
Curaleaf Holdings, Inc. (
CSE: CURA
) (
OTCQX: CURLF
), a leading international provider of consumer products in cannabis,
announced
a first-of-its-kind strategic partnership between its Select brand and legendary music and culture authority Rolling Stone. Together, the leading lifestyle brand in cannabis joins the most prominent voice in music and pop culture to celebrate the symbiotic relationship between music and cannabis. The long term partnership leverages Select’s resources and experience creating progressive, industry-leading cannabis products alongside Rolling Stone, whose DNA lives at the intersection of music’s past, present and future.
The new line of co-branded Rolling Stone by Select products will include two product formats to start, including Select’s first-ever pre-roll, as well as “The Cliq,” Select’s newest proprietary pod system. Both formats will feature three strains and flavor profiles hand-selected by Rolling Stone to celebrate some of the most well-known and genre-defining artists and sounds in music history. The line includes a berry-forward “Overdrive” Sativa, complex and full-bodied “Reverb” Indica, and a fruity and calming “Phaser” Hybrid.
“Part of my job at Curaleaf is building brands people love. Select is a brand built around the relentless pursuit of progress, and going to great lengths to create the best possible experience for our consumer. This is a synergy we are honored to share with Rolling Stone. They are known for having one of the most authentic and discerning voices in modern journalism, and, as part of that, they’ve included cannabis in their coverage for the past 50 years – something many other publications are only just starting to do today. We’re honored and thrilled that the Rolling Stone team believes in our vision, our products and our people to create and deliver the highest-quality cannabis products and experiences in the industry,” said Joe Bayern, CEO of Curaleaf.
“Music and Cannabis go hand in hand,” said Rolling Stone President and Chief Operating Officer Gus Wenner. Rolling Stone has a legacy of celebrating this connection and a long history of reporting on the fight to legalize cannabis. “We are thrilled to have found a perfect partner in Curaleaf who gives us the opportunity to design a product that elevates the music listening experience and celebrates the deep connection between the two.”
Select’s commitment to enriching communities and creating inclusive, meaningful experiences and Rolling Stone’s world class storytelling and culture-defining content inspired the inception of a first-of-its-kind retail space opening in Las Vegas in 2022. Additional details on the space will be released in the near future.
In Nevada, Rolling Stone by Select products will be distributed through Select’s wholesale partners and at Curaleaf’s owned dispensaries, including Acres by Curaleaf and Curaleaf Las Vegas Boulevard. For more information about Select’s portfolio of products or find a dispensary near you that carries Select products, visit us at
www.selectcannabis.com
.
Khiron Life Sciences Corp. (
TSXV: KHRN
) (
OTCQX: KHRNF
), a vertically integrated medical cannabis leader with core operations in Latin America and Europe,
announced
the receipt of the Company’s largest ever shipment of EU-GMP certified medical cannabis product for distribution and sale into the German market.
Recently, Khiron’s German distribution partner, Nimbus Health GmbH, received approximately 36kg of Khiron 20/1 medical cannabis product, a THC-dominant cannabis flower product which has been prescribed to patients in the UK since July 2020. The new product increases the Company’s German medical cannabis offering, which now includes both THC-dominant and CBD-dominant Cannabis products. As a result of the shipment, the Company expects to increase its European medical cannabis sales in the second quarter of 2021.
“As we launch another new product into Germany and more than triple our shipment volumes, our European team continues to demonstrate strong execution and leadership. In line with our Mission of improving patients’ lives through medical cannabis, we continue to expand our offering of EU-GMP cannabinoid-based medicines. Simultaneously, we are developing additional products based on our Colombian extracts, whose efficacy and safety are backed by real-world evidence from over 20,000 prescriptions,” comments Alvaro Torres, CEO and Director.
Khiron’s European product portfolio now includes both THC-dominant and CBD-dominant cannabis flower products available for sale in Germany and the UK, two of the largest chronic pain markets in Europe. Over the coming months, the Company plans to increase patient access by expanding its product offering and medical education initiatives.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at
https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks and other ideas on our site using our
list of top stock trading apps
including Robinhood , Acorn, Stash and others.
To hear more Investorideas.com podcasts visit:
https://www.investorideas.com/Audio/
.
The Investorideas.com podcasts are also available on iTunes (Apple Podcasts), Audible, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Play Music and most audio platforms available.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com – News that Inspires Big Investing Ideas
Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns:
Crypto Corner
,
Play by Play
sports and stock news,
Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast
,
Cleantech and Climate Change
,
Exploring Mining
,
Betting on Gaming Stocks Podcast
and the
AI Eye Podcast
.
Disclaimer/Disclosure:
Investorideas.com
is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.
Contact management and IR of each company directly regarding specific questions.
More disclaimer info:
https://www.investorideas.com/About/Disclaimer.asp
Learn more about publishing your news release and our other news services on the Investorideas.com newswire
https://www.investorideas.com/News-Upload/
and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
https://www.facebook.com/Investorideaspotcasts/
https://www.instagram.com/investorideas_potcast/
Download our
Mobile App
for iPhone and Android
Contact Investorideas.com
800-665-0411
